BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 30671800)

  • 1. Is Resection of Primary Midgut Neuroendocrine Tumors in Patients with Unresectable Metastatic Liver Disease Justified? A Systematic Review and Meta-Analysis.
    Tsilimigras DI; Ntanasis-Stathopoulos I; Kostakis ID; Moris D; Schizas D; Cloyd JM; Pawlik TM
    J Gastrointest Surg; 2019 May; 23(5):1044-1054. PubMed ID: 30671800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Midgut Neuroendocrine Tumors with Liver-only Metastases: Benefit of Primary Tumor Resection.
    Gangi A; Manguso N; Gong J; Crystal JS; Paski SC; Hendifar AE; Tuli R
    Ann Surg Oncol; 2020 Oct; 27(11):4525-4532. PubMed ID: 32394299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of Cytoreductive Surgery for Metastatic Low-Grade Neuroendocrine Tumors in the Setting of Extrahepatic Metastases.
    Chan DL; Dixon M; Law CHL; Koujanian S; Beyfuss KA; Singh S; Myrehaug S; Hallet J
    Ann Surg Oncol; 2018 Jun; 25(6):1768-1774. PubMed ID: 29560571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary Tumor Resection Offers Survival Benefit in Patients with Metastatic Midgut Neuroendocrine Tumors.
    Polcz M; Schlegel C; Edwards GC; Wang F; Tan M; Kiernan C; Solórzano CC; Idrees K; Parikh A; Bailey CE
    Ann Surg Oncol; 2020 Aug; 27(8):2795-2803. PubMed ID: 32430752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic review of resecting primary tumor in MNETs patients with unresectable liver metastases.
    Guo J; Zhang Q; Bi X; Zhou J; Li Z; Huang Z; Zhang Y; Li M; Chen X; Hu X; Yihebali C; Liang J; Liu J; Zhao J; Cai J; Zhao H
    Oncotarget; 2017 Mar; 8(10):17396-17405. PubMed ID: 28030811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroendocrine Liver Metastasis: Prognostic Implications of Primary Tumor Site on Patients Undergoing Curative Intent Liver Surgery.
    Spolverato G; Bagante F; Aldrighetti L; Poultsides G; Bauer TW; Field RC; Marques HP; Weiss M; Maithel SK; Pawlik TM
    J Gastrointest Surg; 2017 Dec; 21(12):2039-2047. PubMed ID: 28744737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surgery Provides Long-Term Survival in Patients with Metastatic Neuroendocrine Tumors Undergoing Resection for Non-Hormonal Symptoms.
    Chakedis J; Beal EW; Lopez-Aguiar AG; Poultsides G; Makris E; Rocha FG; Kanji Z; Weber S; Fisher A; Fields R; Krasnick BA; Idrees K; Marincola-Smith P; Cho C; Beems M; Pawlik TM; Maithel SK; Schmidt CR; Dillhoff M
    J Gastrointest Surg; 2019 Jan; 23(1):122-134. PubMed ID: 30334178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic surgery for metastases from neuroendocrine tumors.
    Sarmiento JM; Que FG
    Surg Oncol Clin N Am; 2003 Jan; 12(1):231-42. PubMed ID: 12735141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resection of the primary tumor improves survival in patients with gastro-entero-pancreatic neuroendocrine neoplasms with liver metastases: A SEER-based analysis.
    Zheng M; Li Y; Li T; Zhang L; Zhou L
    Cancer Med; 2019 Sep; 8(11):5128-5136. PubMed ID: 31328428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver Resection for Neuroendocrine Tumor Liver Metastases Within Milan Criteria for Liver Transplantation.
    Ruzzenente A; Bagante F; Bertuzzo F; Aldrighetti L; Campagnaro T; Ercolani G; Conci S; Giuliante F; Dore A; Ferrero A; Torzilli G; Grazi GL; Ratti F; Cucchetti A; De Rose AM; Russolillo N; Cimino M; Perri P; Guglielmi A; Iacono C
    J Gastrointest Surg; 2019 Jan; 23(1):93-100. PubMed ID: 30242647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Impact of Extent of Liver Resection Among Patients with Neuroendocrine Liver Metastasis: an International Multi-institutional Study.
    Sham JG; Ejaz A; Gage MM; Bagante F; Reames BN; Maithel S; Poultsides GA; Bauer TW; Fields RC; Weiss MJ; Marques HP; Aldrighetti L; Pawlik TM; He J
    J Gastrointest Surg; 2019 Mar; 23(3):484-491. PubMed ID: 29980977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small intestinal neuroendocrine tumors with liver metastases and resection of the primary: Prognostic factors for decision making.
    Bertani E; Falconi M; Grana C; Botteri E; Chiappa A; Misitano P; Spada F; Ravizza D; Bazolli B; Fazio N
    Int J Surg; 2015 Aug; 20():58-64. PubMed ID: 26074290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of cytoreductive operations for peritoneal carcinomatosis with or without liver cytoreduction in patients with small bowel neuroendocrine tumors.
    Wonn SM; Limbach KE; Pommier SJ; Ratzlaff AN; Leon EJ; McCully BH; Pommier RF
    Surgery; 2021 Jan; 169(1):168-174. PubMed ID: 32473829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective cytoreduction can be achieved in patients with numerous neuroendocrine tumor liver metastases (NETLMs).
    Scott AT; Breheny PJ; Keck KJ; Bellizzi AM; Dillon JS; O'Dorisio TM; Howe JR
    Surgery; 2019 Jan; 165(1):166-175. PubMed ID: 30343949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic Resection for Non-functional Neuroendocrine Liver Metastasis: Does the Presence of Unresected Primary Tumor or Extrahepatic Metastatic Disease Matter?
    Xiang JX; Zhang XF; Beal EW; Weiss M; Aldrighetti L; Poultsides GA; Bauer TW; Fields RC; Maithel SK; Marques HP; Pawlik TM
    Ann Surg Oncol; 2018 Dec; 25(13):3928-3935. PubMed ID: 30218247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of extrahepatic disease among patients undergoing liver-directed therapy for neuroendocrine liver metastasis.
    Ejaz A; Reames BN; Maithel S; Poultsides GA; Bauer TW; Fields RC; Weiss M; Marques HP; Aldrighetti L; Pawlik TM
    J Surg Oncol; 2017 Dec; 116(7):841-847. PubMed ID: 28650564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relevant prognostic factors in patients with stage IV small intestine neuroendocrine neoplasms.
    Maurer E; Heinzel-Gutenbrunner M; Rinke A; Rütz J; Holzer K; Figiel J; Luster M; Bartsch DK
    J Neuroendocrinol; 2022 Jan; 34(1):e13076. PubMed ID: 34964186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surgical resection of neuroendocrine tumor liver metastases as part of multimodal treatment strategies: A propensity score matching analysis.
    Schreckenbach T; Hübert H; Koch C; Bojunga J; Schnitzbauer AA; Bechstein WO; Holzer K
    Eur J Surg Oncol; 2019 May; 45(5):808-815. PubMed ID: 30611565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver-directed surgery of neuroendocrine metastases: What is the optimal strategy?
    Maxwell JE; Sherman SK; O'Dorisio TM; Bellizzi AM; Howe JR
    Surgery; 2016 Jan; 159(1):320-33. PubMed ID: 26454679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Palliative cytoreductive surgery versus other palliative treatments in patients with unresectable liver metastases from gastro-entero-pancreatic neuroendocrine tumours.
    Gurusamy KS; Pamecha V; Sharma D; Davidson BR
    Cochrane Database Syst Rev; 2009 Jan; 2009(1):CD007118. PubMed ID: 19160322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.